Reported 9 months ago
On June 26, 2024, at 4:10 pm US Eastern Time (1795), benefiting from the increased shipment of American leukemia drugs and strong growth in the Asian market, analysts are optimistic that the second-quarter revenue will grow compared to the previous quarter and the same period last year. On the 26th, it attracted three major institutional investors to simultaneously buy 2,185 shares, driving the stock price back above the $300 mark, with an increase of 7.06% to $310.5, steadily above the average line with the KD indicator turning bullish. With a volume of 14,404 shares, it can be considered as an attacking volume, favorable for the bulls. In order to expand into the ASEAN market, they announced the acquisition of Teva Pharmaceuticals' Thai subsidiary in early June, marking their first merger and acquisition deal in Southeast Asia. This move will not only expand their oncology and gynecology product lines but also provide access to Teva's ophthalmic and respiratory product portfolios, allowing them to enter the pharmacy channels in Thailand.
Source: YAHOO